Research programme: antioxidants - CeNeS
Alternative Names: Antioxidants research programme - CeNeSLatest Information Update: 28 Nov 2021
At a glance
- Originator CeNeS Pharmaceuticals
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 12 Sep 2002 CeNeS has stopped its research activities and is concentrating on development of late stage candidates
- 12 Sep 2002 Discontinued-preclinical for Alzheimer's disease in United Kingdom (unknown route)
- 02 Oct 2001 This programme is still being actively researched